Investing in SomaLogic

SomaLogic, Inc. is a privately held biotechnology company with headquarters in Boulder, Colorado.

For all investment questions, please contact us.

A recent presentation outlining our technology, applications and business plan can be downloaded here.

Interested in potential investment opportunities?

SomaLogic Business News

SomaLogic adds three new SomaSignal™ tests to its current offerings

SomaLogic announced today that it has launched three additional SomaSignal™ tests to further empower individuals to manage their state of health more effectively. These new blood-based tests measure glucose tolerance, visceral fat and resting energy rate.
read more

Blood test beats traditional predictors of multiple disease risks

Proteins in our blood could in future help provide a comprehensive “Liquid Health Check,” assessing our health and predicting the likelihood that we will we will develop a range of diseases, according to research published today in Nature Medicine. The study, by an international team of researchers led by scientists at SomaLogic, the University of California, San Francisco and Cambridge University in the UK, shows that large-scale measurement of proteins in a single blood test can provide important information about a wide range of health factors and can help to predict multiple disease risks. 
read more

SomaLogic announces three new appointments to board of directors

SomaLogic, a privately held precision health information company, announced today that it has appointed Anne Margulies, Harvard University Vice President and Chief Information Officer, Franck J. Moison, former Vice Chairman of Colgate-Palmolive, and private investor Richard “Rick” Post to its board of directors.
read more

SomaLogic significantly expands key strategic collaboration with Novartis

SomaLogic, Inc., announced today that it has entered into a new ten-year agreement with its long-time pharmaceutical partner, Novartis, to expand the application of SomaLogic’s leading proteomic technology across the company’s drug discovery and development efforts. The agreement includes plans to analyze at least 250,000 clinical samples from across the Novartis drug development portfolio.
read more

Patrick Terry announced as first Chief Commercial Officer of SomaLogic

SomaLogic announced today that Patrick Terry has joined the company as its first Chief Commercial Officer (CCO). A serial entrepreneur, biomedical science enthusiast and patient advocate, Terry is uniquely qualified to lead the commercialization of SomaLogic’s growing portfolio of protein-based precision health information products.
read more

SomaLogic launches its first SomaSignal™ tests in select medical practices

SomaLogic today launched its first seven SomaSignal™ tests, which are delivered simultaneously to provide actionable health information across a diverse set of human diseases and conditions. Each SomaSignal™ test is built on SomaLogic’s proprietary SomaScan® Platform, which measures thousands of human proteins in a single blood sample. The company expects that eventually there will be hundreds of different SomaSignal™ tests on the SomaScan® Platform.
read more

SomaLogic’s clinical laboratory re-accredited by the College of American Pathologists

SomaLogic announced today that its United States clinical laboratory (CLIA laboratory) has been re-accredited by the College of American Pathologists (CAP). The successful renewal of CAP accreditation is based on the results of a recent on-site inspection designed to ensure the highest laboratory standards.
read more


For all the latest SomaLogic news, please visit our News and Events page.